Articles

Poll

Aaron Waxman, MD, PhD, discusses sotatercept’s new indication and recommendation in patients newly diagnosed with PAH at intermediate to high risk.

Catch up on key FDA approvals, major trial updates, and critical clinician insights from the last 3 months.

Ryaltris pediatric approval, lonvo-z and deucrictibant HAE filings, PVX108 Fast Track, and Palforzia's exit headline Q3 2026 allergy news.

Catch up on key FDA approvals, major trial updates, and critical clinician insights from the last 30 days.

The FDA set a June 18, 2027, PDUFA date for the subcutaneous GP IIb/IIIa inhibitor, based on phase 3 CeleBrate data.

Joseph Rossano, MD, MS, discusses the SCOUT-HCM trial, mavacamten’s expanded indication, and what it means for pediatric oHCM.

DBV has requested priority review for the epicutaneous patch, supported by phase 3 VITESSE data showing a 31.8-point responder rate gain vs placebo.

FDA approved mavacamten for oHCM in children weighing 30 kg or more after SCOUT-HCM showed a 48.0-mm Hg Valsalva LVOT gradient reduction vs placebo.